Study Summary
This trial is testing neratinib, an aromatase inhibitor, and trastuzumab as a treatment for breast cancer.
- Breast Cancer
- HER2-positive Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Triple-Positive Breast Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: 24 weeks
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
A
1 of 1
Experimental Treatment
48 Total Participants · 1 Treatment Group
Primary Treatment: A · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 19 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
For what purpose is A commonly prescribed?
"A is a viable option for managing brca1 gene-related issues, including breast cancer and inflammatory breast cancer (IBC). Additionally, 2 to 3 years of tamoxifen therapy can be utilized in tandem with A." - Anonymous Online Contributor
Could you provide an account of other experiments conducted with A?
"Presently, there are 362 active clinical trials researching A with 91 of those studies being in Phase 3. These investigations are primarily taking place in Seattle, Washington; however, there is a total of 26633 sites conducting research related to this topic." - Anonymous Online Contributor
Does this research endeavor still accept participants?
"According to clinicaltrials.gov, recruitment for this medical trial is still ongoing. The research project was first uploaded on the 21st of July 2022 and underwent its last modification on the 10th of October 2022." - Anonymous Online Contributor
Are there any known dangers associated with utilizing A?
"This Phase 2 trial has not yet yielded efficacy data, thus our team at Power gave a safety rating of 2 for medication A." - Anonymous Online Contributor
How many participants are currently undergoing treatment in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this research is still in the process of recruiting participants for its trials which first began on July 21st 2022 and was most recently revised on October 10th 2022. 48 patients are needed from 1 single medical site." - Anonymous Online Contributor